Abstract Introduction Human mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. Methods Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo)adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included. Results The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; P = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 ± 0.22 and 0.13 ± 013; P = 0.29). Furthermore, there was no difference in disease-free (P = 0.63) or overall survival (P = 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo)adjuvant chemotherapy was not predictive of recurrence. Discussion There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence.
Introduction
Breast cancer is the most frequent cancer in women in Europe and North America, and the second cause of death in females who develop cancer [1] . At diagnosis, up to 90% of patients present with disease limited to the breast and axillary lymph nodes. However, in more than a third, the disease will relapse later on due to progression of clinically occult disease.
Tumour size and extent of axillary node involvement are considered the two strongest predictors of breast cancer recurrence, but in some series the detection of bone marrow metastases by immunocytochemistry was also shown to correlate with poor prognosis with a shorter disease-free survival [2] . The detection of circulating tumour cells has been reported by several groups in patients with localised [3] [4] [5] [6] and metastatic [7] breast cancer. Circulating tumour cells may lead to the development of metastases and their detection in the peripheral blood of breast cancer patients may thus impact on patient's prognosis [8] . In some series, the number of circulating tumour cells before treatment is an independent predictor of progression-free and overall survival in patients with metastatic breast cancer [7] . However, there is no clear evidence that more aggressive therapy will contribute to improved survival in such patients [9] .
Several polymerase chain reaction (PCR)-based methods have been used to detect circulating breast cancer cells. There are different molecules that can be used as markers, but an ideal marker should be specific to the tumour cells and not present in normal cells or in the tissue from which the tumour has originated. However, few molecules fulfil these requirements [10] . In contrast to hematological malignancies, solid tumours rarely present specific diagnostic genetic changes. In order to overcome this limitation, tissue-specific markers have been evaluated as potential molecular targets for the detection of occult tumour cells [11] [12] [13] . Cytokeratin transcripts (CK19 and CK20) have been widely used in the detection of occult breast cells, but we and others have reported low specificity of these assays [14] [15] [16] . The human mammaglobin (hMAM) gene has been proposed as a promising diagnostic marker for breast cancer cells over the last 10 years. This gene, identified by Watson and Fleming in 1996 [17] by differential display PCR, is localised on chromosome 11q13. The protein encoded by hMAM belongs to the uteroglobin/Clara cell family of small epithelial secretory proteins. In contrast to cytokeratins, hMAM was reported to be exclusively expressed in mammary epithelium and overexpressed in some breast cancers, making it a potential useful RT-PCR target for breast cancer cell detection in hematopoietic products [17, 18] . High levels of hMAM in primary breast tumours reflect a less aggressive tumour phenotype and are correlated with the expression of estrogen and progesterone receptors, diploid DNA content, low Ki67 labelling index, low nuclear grade and absence of axillary nodal invasion [19] . The evaluation of hMAM as a molecular marker of lymph node metastases demonstrated the utility of hMAM-specific PCR in the detection of micrometastases [20] [21] [22] [23] [24] [25] . Zach et al. [26] were the first to develop a nested PCR assay for the detection of hMAM mRNA in the peripheral blood of breast cancer patients. They reported that the incidence of detectable hMAM transcripts in peripheral blood was correlated with disease burden: present in 5 of 18 (28%) patients at diagnosis, in 3 of 53 (6%) with no evidence of disease and in 21 of 43 (49%) with metastatic disease. Similarly, Cerveira et al. [27] reported that the proportion of patients with breast cancer with detectable hMAM in peripheral blood samples increased with disease stage: 0% for stage 0, 23% for stage I, 35% for stage II, 50% for stage III and 73% for stage IV.
Five years ago, our group [28] analysed the expression of hMAM transcript by RT-PCR and evaluated the sensitivity and specificity of this molecular marker in the detection of minimal residual disease using patients and volunteers' samples as well as breast cancer cell lines. In addition, we analysed the incidence of hMAM expression in bone marrow, peripheral blood and peripheral blood progenitor cell samples collected from breast cancer patients. We observed that the hMAM mRNA was a sensitive and specific marker of breast cancer cells. However, whether hMAM transcript analysis can detect occult circulating breast cancer cells before the development of overt distant metastases still remains elusive.
In the present study, we performed the prospective evaluation of the contamination of peripheral blood by malignant cells in 321 patients with breast cancer treated with adjuvant or neoadjuvant chemotherapy. The aim of this study was to investigate if the detection of hMAM transcript in the peripheral blood of breast cancer patients (without metastases at diagnosis) was a predictive factor for the development of clinically detectable metastatic disease.
Materials and methods

Patients' eligibility
Patients were eligible if they had histological or cytological diagnosis of breast cancer, the disease was confined to the breast and the homolateral axillary lymph nodes and if they were to be treated with adjuvant or neoadjuvant chemotherapy.
Controls
To evaluate the specificity of the assay, serial blood samples from healthy volunteer controls were also studied for hMAM mRNA detection. These controls were selected among the staff of the Centro de Investigação de Patobiologia Molecular (CIPM) and among the physicians of the Hematology and Medical Oncology Services.
Blood sample collection
Blood samples were to be collected up to 5 years after diagnosis. The first sample was to be collected before the beginning of the adjuvant/neoadjuvant chemotherapy. The remaining samples were collected at each clinic visit: every three months during the first year, every four months during the second year, every six months during the third and fourth year and annually thereafter. This study was approved by the institutional ethics committee and written informed consent was obtained from all participating patients.
RNA extraction
Total RNA was extracted from nucleated cells of peripheral blood and from T47D human breast cancer cell line, using TRIZOL reagent (Life Technologies, Inc., Gaithersburg, MD, USA) according to the manufacturer's protocol. Quantification and purity assessment were performed by optical density measurement at 260 and 280 nm. RNA samples were stored at -70°C.
RT-PCR
Human mammaglobin mRNA expression was analysed by RT-PCR as described previously [28] . Each sample was analysed twice and considered positive if a specific amplification was detected in at least one PCR assay. Negative controls for cDNA synthesis and PCRs, in which the template was replaced by sterile water, were included in each experiment. T47D human breast cancer cell line was used as positive control. T47D total RNA was serially diluted into Esherichia coli tRNA and two concentrations were tested in each PCR: 1 and 10 -6 lg of positive RNA in a total of 1 lg. 10 -6 corresponds to the previously established limit of sensitivity [28] . RNA integrity and efficiency of cDNA synthesis were analysed in each sample by performing RT-PCR amplification for the bcr housekeeping gene. Rigorous precautions were taken to eliminate the possibility of false-positive results [29] .
Statistical analysis
Statistical procedures were carried out in order to assess the putative predictive value of hMAM gene expression in detecting breast cancer recurrence. Estimated disease-free and overall survivals for negative and positive hMAM peripheral blood samples were computed with the productlimit estimator (Kaplan-Meier method) and compared with the log-rank test. Missing values for hMAM peripheral blood samples were not imputed. For disease-free survival, recurrence of breast cancer (local, regional or systemic), contralateral breast cancer and death from any cause were considered as events. For survival, death from any cause was considered an event. Chi-Square (v 2 ) and Fisher's Exact tests were used to compare recurrence between patients with negative and positive hMAM samples, and v 2 test for trend was used in case of ordered categories. To explore the effects of multiple predictor independent variables at the same time, a Cox proportional hazards regression model was used. Covariates studied included age, the standard prognostic factors for breast cancer tumor size, axillary lymph node involvement and hormonal receptor status as well as hMAM peripheral blood detection. Statistical analysis was performed using Graph Pad Prism version 2.0 (San Diego, CA, USA) and Intercooled Stata 9.2 for Windows (StataCorp., College Station, Texas, USA).
Results
Patient population
Three hundred and twenty one patients (320 women and 1 man) with breast cancer were included in the present study. In all patients the disease was limited to the breast and to the homolateral axillary lymph nodes. During the followup (median: 43 months; range: 3-74) 59 of 321 patients (18.4%) developed metastases and 32 of these patients (54.2%) died due to disease progression. In two other patients the death was not caused by breast cancer (lymphoma and leukemia, respectively). The 5 year overall and disease-free survival estimates were 85.2% and 76.9%, respectively (Fig. 1) . The recurrence was exclusively local in 6 patients, exclusively distant in 49 patients and combined in 4 patients. Distant recurrences occurred mostly in bone, lymph nodes and liver as the first site of metastatic disease. Six patients were lost to follow-up. Five patients developed a second cancer: contralateral breast cancer in three, lymphoma in one and leukemia in another. Only blood samples collected before recurrence or detection of a second cancer were included in the present analysis. The clinicopathological characteristics of patients are presented in Table 1 . The median age at diagnosis was 51 years (range: 22-81). Most patients presented with a ductal carcinoma (89.1%), had high expression of estrogen and/or progesterone receptors (76.0%) and no or inconclusive HER-2/neu overexpression (81.3%). Axillary lymph node involvement was detected in 57.8% of patients initially treated with surgery and in 71.7% of those first treated with neoadjuvant chemotherapy followed by surgery.
Peripheral blood samples collection
For logistic reasons, there was no strict adherence to the protocol sample collection schedule. Thus, the time between sample collection as well as the number of samples collected per patient varied between patients.
A total of 2,122 peripheral blood samples were collected during a median follow-up of 43 months (range: 3-74). The median number of peripheral blood samples collected per patient was 7 (range: 1-10).
Analysis of hMAM mRNA expression in peripheral blood samples collected from patients before the beginning of systemic treatment (baseline) and in healthy controls
In 43 patients (13.4% of study population) the baseline peripheral blood sample, before administration of chemotherapy, was not collected. Overall a total of 52 of 278 (18.7%) samples were positive for hMAM mRNA. We did not observe a significant difference between the frequency of hMAM-positive baseline samples from patients who later developed a recurrence (11/49; 22.4%) and from patients who have remained disease free (41/229; 17.9%; P = 0.46). Thus, the detection of hMAM transcript in peripheral blood before the administration of (neo)adjuvant systemic chemotherapy did not predict for the development of metastases.
In order to analyse the specificity of RT-PCR assay, peripheral blood from 28 healthy donors (3 men and 25 women) were tested. Multiple samples were obtained from most volunteers (median: 2.5; range: 1-7) over a median period of 25.5 months (range: 0-47). One sample out of two samples from the same healthy donor was positive. All samples from the remaining controls were negative. Thus the false positive rate among healthy controls was 1.3% (1/77).
Analysis of hMAM mRNA expression in peripheral blood samples collected after systemic (neo)adjuvant chemotherapy A total of 1844 peripheral blood samples were collected during follow-up. Of those, 241 (13.1%) were positive for hMAM transcript. One hundred and seventy seven (55.1%) patients had at least one positive sample during the follow-up.
To investigate the impact on the risk of relapse of the detection of mammaglobin transcript in serial blood samples from patients with breast cancer, we calculated the ratio between the total number of positive samples and the total number of analysed samples per patient, which we denominated hMAM SCORE. The hMAM SCORE could not be calculated in 6 patients, because no follow-up samples were collected up to the date of recurrence or last follow-up. The hMAM SCORE was not significantly different between patients who relapsed (mean: 0.15 ± 0.22; N = 54) and patients who remained disease free (mean: 0.13 ± 0.13; N = 261; P = 0.29). Thus the frequency of the detection of hMAM transcript in blood samples after the administration of (neo)adjuvant systemic chemotherapy is not associated with the development of disease recurrence. In only 10 of 54 (18.5%) patients that relapsed, was the hMAM transcript detected in the last blood sample collected before recurrence, with a median time between sample collection and the detection of disease recurrence of 5 months (range: 1-24). Seven of these 10 patients (70%) have already died as a result of disease progression. In contrast hMAM mRNA was found in the most recently collected sample of 20 of 261 (7.7%) patients that have remained disease free (P = 0.01).
To analyse further the clinical relevance of a positive hMAM sample collected during the follow-up, we evaluated the predictive value for disease recurrence of the detection of any single positive peripheral blood sample and of two consecutive positive peripheral blood samples. In only 7 of 177 (4%) positive follow-up samples did breast cancer recurrence develop before the collection of the next peripheral blood sample. Furthermore, if two consecutive hMAM positive samples are considered, in only 1 of 28 (4%) instances did the disease recur before the collection of the next follow-up samples. Correlation between the detection of hMAM mRNApositive cells in peripheral blood samples and the clinicopathological characteristics of patients There was no association between the presence of hMAM mRNA-positive circulating cells before the administration of chemotherapy and clinicopathological characteristics such as age at diagnosis, T stage, axillary lymph node involvement, hormone receptor status or tumour grade (data not shown). In contrast, almost all patients (34/36; 94%) with HER-2 positive tumours had baseline peripheral blood samples negative for hMAM mRNA, compared to 77% of patients with HER-2 negative tumours (104/135; P = 0.02).
To further investigate the clinical impact of hMAM expression in blood samples collected after the administration of systemic therapy, we analysed the correlation between the hMAM SCORE and clinicopathological features. There was no association between the hMAM SCORE and age at diagnosis, T stage, hormone receptors expression, HER-2 status and tumour grade (data not shown). In contrast, there was an association of the hMAM SCORE and axillary lymph node involvement, but only for the subgroup of patients initially submitted to surgery. The mean hMAM SCORE was 0.23 for patients with C10 positive nodes and 0.11 for negative nodes, 0.14 for 1-3 positive nodes and 0.13 for 4-9 positive nodes (P = 0.03). However, no such association was documented for the subgroup of patients who received neoadjuvant chemotherapy first.
Survival analysis
The Kaplan-Meier estimates of overall survival and diseasefree survival for patients with hMAM mRNA-positive and negative baseline peripheral blood samples were not different ( Fig. 1 , P = 0.57 and P = 0.63, respectively). Furthermore, we did not observe significant differences in disease-free survival between patients whose follow-up samples were always hMAM negative and patients with at least one hMAM positive sample, when considering samples collected at different cut-off time points up to 24 months after diagnosis. However when samples collected up to 36 and 48 months were included, hMAM mRNA positivity was associated with improved overall and disease-free survival (P B 0.05), contrary to the study hypothesis and difficult to understand biologically. Disease free survival curves stratified for hMAM positivity at baseline, up to 18 months and up to 48 months are shown in Fig. 2 .
Multivariate analysis for disease-free survival A Cox regression multivariate analysis was performed to estimate the impact on disease-free survival of several clinicopathologic parameters and of the mammaglobin transcript detection in peripheral blood. Several models were studied to incorporate hMAM results up to several different follow-up time points ( Table 2) . As expected, age at diagnosis, T stage, axillary lymph node involvement and hormonal therapy were significant independent prognostic factors in all models. In contrast, the detection of hMAM mRNA before the administration of systemic therapy (baseline), as well as in at least one blood sample collected after (neo)adjuvant chemotherapy, were not independent prognostic factors for disease-free survival. Furthermore, a positive hMAM blood sample collected up to 36 or 48 months after diagnosis was an independent prognostic factor for better disease-free survival, again contrary to study hypothesis.
Discussion
Circulating tumour cells can be detected in the peripheral blood of patients with a wide range of malignant tumours of epithelial origin. These cells are present not only in patients with metastatic disease, but also in those whose tumours are apparently localised [30] . This is also observed in breast cancer, where malignant cells seem to spread into the bloodstream in early stages of tumour development [31, 32] . Many patients subsequently relapse at distant sites despite adequate local treatment, presumably as a result of undetected spread of the tumour cells before the removal of the primary tumour [30] .
RT-PCR has been used for the detection of specific tumour cell markers, thus indicating the presence of circulating breast tumour cells in the blood, with varying degrees of sensitivity and specificity [33] . The hMAM gene was described to be a potentially specific marker for the detection of circulating breast cancer cells [34] . However, the clinical relevance of the detection of hMAM positivetumour cells in the peripheral blood of patients with localised breast cancer still remains elusive, since several papers report conflicting results [35] [36] [37] .
In the present study we performed the prospective analysis of hMAM mRNA detection in serial samples of peripheral blood collected from patients with non-metastatic breast cancer. We observed high degree of specificity of the RT-PCR assay, since there was only a single positive result among 77 healthy volunteers' peripheral blood samples. Despite the high specificity of hMAM RT-PCR assay, the induction by several cytokines of mammaglobin expression in cell lines, in bone marrow and in peripheral stem cells from patients without epithelial cancer has been reported [38] . This may explain the occurrence of a single false-positive result in a healthy donor sample. In addition, other groups reported the detection of mammaglobin transcript in non-breast tissues, such as ovary, uterus, cervix and sebaceous glands [37, 39, 40] .
We detected the hMAM transcript in 52 of 278 (18.7%) patients, before the administration of any adjuvant or neoadjuvant therapy. Thirty eight of 212 (17.9%) patients with operable breast cancer presented hMAM positivebaseline sample. Similarly, Ntoulia et al. [41] also reported the expression of hMAM mRNA in 14/101 (13.9%) peripheral blood samples collected before the start of adjuvant chemotherapy, from patients with operable breast cancer. In contrast, Cerveira et al. [19] documented peripheral blood hMAM positivity in 41% of breast cancer patients, by one-step RT-PCR. They hypothesized that the low percentages of positive results reported in other studies could be related to low sensitivity of the RT-PCR assay. However, our assay has a limit of detection of one tumour cell in 10 6 hematological control cells when using the T47D cell line [28] , which was similar to the reproducible limit of detection obtained by Cerveira et al. [27] . Needless to mention, the absence of hMAM mRNA in blood samples does not exclude the presence of circulating tumour cells. The detection of these cells may depend on the number of cancer cells present in the blood and also on the hMAM expression level by individual cells [42] . Recently, quantitative real-time fluorescence-based RT-PCR has become the ideal method for the detection of RNA [43] . Some studies have applied this methodology in the analysis of mammaglobin mRNA expression in peripheral blood samples of breast cancer patients and still reported low sensitivity [36, 44] . Although real-time RT-P CR allows the quantification of the transcript of interest, conventional RT-PCR is still a good method for a prospective study with a high number of samples. At the time this study started, quantitative real-time fluorescence-based RT-PCR was not widely available. When this technology became available at our center, we decided not to change the methodology half-way into the study, without strong evidence that switching to quantitative real-time RT-PCR would dramatically alter the test sensitivity and specificity. In this study, the detection of the mammaglobin transcript in peripheral blood of breast cancer patients before the start of systemic therapy was not associated with clinical relapse (22.4% of positivity in patients who relapsed and 17.9% in patients who remained disease free; P = 0.46). Furthermore, the Kaplan-Meier estimates of overall (P = 0.57) and disease-free survival (P = 0.63) rates for hMAM transcript positive and negative patients were not different. Our results are partially concordant with Ntoulia et al. [41] , who observed significant differences in the disease-free survival, but not in overall survival, according to hMAM detection.
To evaluate the impact of the detection of the mammaglobin transcript in blood samples before systemic therapy, we analysed the association between several clinicopathological characteristics and the hMAM mRNA detection. We did not observe an association between hMAM expression and several parameters such as age at diagnosis, T stage, number of positive axillary lymph nodes, hormone receptor positivity or tumour grade, as previously reported [42, 45] . However, we detected an inverse association between mammaglobin mRNA expression in blood baseline samples and HER-2 overexpression or amplification in tumours. This is in contrast with the association of HER-2 overexpression and tumour aggressiveness [46] but in agreement with the reported lower expression of hMAM by breast tumour cells with a more aggressive phenotype documented by no expression of hormone receptors and high nuclear grade [19] . Thus, tumours with HER-2 overexpression may express lower or undetectable levels of hMAM transcript, which has not been studied before.
Not only didn't we document an association between hMAM detection in peripheral blood at diagnosis and disease recurrence or survival, we did not document such an association with the detection of mammaglobin transcript in blood samples collected after the administration of systemic (neo)adjuvant chemotherapy either. Patients who relapsed had a similar hMAM SCORE to patients who remained in remission (mean: 0.15 ± 0.22; N = 54 vs. 0.13 ± 013; N = 261; P = 0.29). Similarly, there was no difference in disease-free survival between patients whose samples were always hMAM negative and patients with at least one hMAM positive peripheral blood sample, when samples collected up to 24 months after diagnosis were analysed (P = 0.05). If later samples were included in the analysis, up to 48 months, patients with at least one hMAM positive sample had better disease-free survival than patients who never had hMAM positive blood samples, contrary to the study hypothesis. Mammaglobin expression by breast cancer cells seems to be correlated with indicators of better prognosis [19] . This may explain why we observed that hMAM positivity in baseline peripheral blood samples was more frequent in patients with HER2-negative tumours than in patients harbouring tumors with HER2 overexpression/ amplification. Thus, hMAM-positive circulating tumour cells may be a surrogate for a more indolent disease with a delayed risk of recurrence. However, Mikhitarian et al. [47] reported that the overexpression of hMAM in peripheral blood samples collected before surgery was significantly associated with high tumour grade and showed a trend towards estrogen receptor-negative high risk breast cancer. Alternatively, since it has been reported that apoptotic cells represent the majority of circulating tumor cells in patients with breast cancer [48] , a potential explanation for the association of hMAM positivity in the blood and improved prognosis could be that hMAM detection is a marker of enhanced chemotherapy effect, leading to increased likelihood of circulating apoptotic tumor cells. However, we have no data to support that the hMAM-positive circulating tumor cells detected by our assay are apoptotic. Using Cox proportional hazards model, after adjustment for significant clinical and pathologic parameters, there was no association of either hMAM mRNA detection in the baseline blood sample or the follow-up samples collected after the administration of (neo)adjuvant chemotherapy and the disease-free survival.
We investigated the association between the hMAM detection and clinicopathological features of the disease. Other than the presence of 10 or more positive axillary lymph nodes, there was no association between hMAM SCORE and clinical or pathologic parameters. Since the number of positive axillary lymph nodes is the most significant poor prognostic factor for patients with early-stage breast carcinoma [49, 50] , an association with hMAM positivity in peripheral blood would be anticipated. However, this association was only documented among patients initially treated with surgery and not among patients for whom neoadjuvant chemotherapy was the first treatment modality. Thus, this association could be spurious and the statistically significant result dependent from multiple comparisons. Similarly, Ignitiadis et al. [6] using CK-19 peripheral blood detection by real-time RT-PCR also failed to document any association between clinicopathologic variables and CK-19 positive peripheral blood samples collected prior to adjuvant chemotherapy. While axillary lymph node involvement predicts for distant metastases, many patients with breast cancer develop systemic disease in the absence of regional node involvement. As discussed by Pantel and Brakenhoff [51] , breast cancer cells may disseminate from the primary tumor to axillary lymph nodes and distant metastatic sites by different routes. These separate routes may depend on different chemokine receptor-ligand axis. For instance CXCL12, the ligand for CXCR4, is strongly expressed in lung, liver, bone marrow and lymph nodes while CCL21, the ligand for CCR7, is strongly expressed in lymph nodes [52] . In a melanoma model, transfection of CCR7 promotes lymph node metastases while transfection of CXCR4 promotes lung metastases [53, 54] . These data indirectly support the absence of relationship between axillary lymph node involvement and detection of circulating breast cancer cells.
In conclusion, despite high specificity of hMAM mRNA detection in peripheral blood samples, we found no evidence that the detection of hMAM in peripheral blood samples either at diagnosis or during follow-up is predictive of breast cancer recurrence. Contrary to the study hypothesis, the detection of at least one positive hMAM blood sample during extended follow-up (beyond 24 months) seemed to be protective against breast cancer recurrence. Since only one blood sample collected from healthy controls was positive for hMAM mRNA, confirming the previously reported specificity of the test, the biological interpretation of transient positive results in these breast cancer patients remains unclear.
